Summary
Studies were designed to investigate the potential importance of calmodulin in release of calcitonin (CT) in response to an increase in the concentration of extracellular Ca.In vitro release of CT from baby rat thyroparathyroids incubated up to 8 h was examined at normal (1 mM) and high (2.5 mM) Ca in serum-free medium in the presence and absence of the potent calmodulin inhibitors, trifluoperazine (TFP) and N-(6-aminohexyl)-5-Cl-1-naphthalene sulfonamide (W-7). The drugs chloropromazine (CLP) and haloperiodol (HAL) which, like TFP, are anti-psychotic agents also were tested. In some studies release of parathyroid hormone (PTH) into medium also was studied. At 2.5 mM Ca, CT release was increased five- tenfold compared with 1 mM Ca while PTH was suppressed by ≈ 80%. The increased release of CT induced by 2.5 mM Ca was inhibited 60–90% by 10−4 M TFP and 10−4 M W-7, but was unaffected by 10−4M CLP or HAL. In the presence of 1 mM Ca, the increased release of PTH also was inhibited significantly by 10−4 M TFP and 10−4 M W-7. In relatedin vivo studies, administration of TFP i.v. to rats just before induction of hypercalcemia with i.v. CaCl2 suppressed the increase in plasma CT normally observed 3 min later in a dose-related manner. The results show that calmodulin inhibitors can inhibitin vitro secretion of CT, and release of PTH as well. Additionally, inhibition of thein vivo CT response to a Ca challenge was observed within minutes of drug administration. The findings support the notion that calmodulin plays an important role in Ca-mediated release of CT from the C-cell.
Similar content being viewed by others
References
Cheung W (1982) Calmodulin: an overview. Federation Proc 41:2253–2257
Levin RM, Weiss B (1976) Mechanism by which psychotic drugs inhibit adenosine cyclic 3′-5′-monophosphate phosphodiesterase of brain. Mol Pharmacol 12:581–589
Levin RM, Weiss B (1979) Selective binding of antipsychotics and other psychoactive agents to the calcium-dependent activator of cyclic nucleotide phosphodiesterase. J. Pharmacol Exp Therap 208:454–459
Lau Y-S, Gnegy ME (1980) Effects of lanthanum and trifluoperazine on [125I] calmodulin binding to rat striatal particulates. J Pharmacol Exp Ther 215:28–34
Raess BU, Vincenzi FF (1980) Calmodulin activation of red blood cell (Ca2++Mg2+)-ATPase and its antagonism by phenothiazines. Mol Pharmacol 18:253–258
Nishikawa N, Hidaka H (1982) Role of calmodulin in platelet aggregation: structure-activity relationship of calmodulin antagonists. J Clin Invest 69:1348–1355
Cooper CW, Ramp WK, Becker DI, Ontjes DA (1977) In vitro secretion of immunoreactive rat thyrocalcitonin. Endocrinology 101:304–311
Cooper CW, Ramp WK, Ross AJ III, Wells SA Jr (1978) Concurrent secretion of calcitonin and parathyroid hormone in vitro from the rat thyroparathyroid complex. Proc Soc Exp Biol Med 158:299–303
Burford HJ, Ontjes DA, Cooper CW, Parlow AF, Hirsch PF (1975) Purification, characterization and radioimmunoassay of thyrocalcitonin from rat thyroid glands. Endocrinology 96:340–348
Cooper CW, Obie JF, Hughes AR, Margules DL, Flynn JJ (1983) Secretion of calcitonin in the genetically obsese Zucker rat (fa/fa). Proc Soc Exp Biol Med 173:48–55
Snedecor GW, Cochran WG (1967) Statistical methods. 6th ed. Iowa State University Press, Ames
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cooper, C.W., Borosky, S.A. Inhibition of secretion of rat calcitonin by calmodulin inhibitors. Calcif Tissue Int 38, 103–108 (1986). https://doi.org/10.1007/BF02556837
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02556837